Vitamin D deficiency linked to abnormal bone and lipid metabolism predicts high-risk multiple myeloma with poorer prognosis

Purpose Vitamin D deficiency is frequent in patients with multiple myeloma (MM), however, its prognostic relevance in MM was rather inconclusive. We first investigated the association of vitamin D deficiency with abnormal bone and lipid metabolism in newly diagnosed multiple myeloma (NDMM), and next assessed the impact of serum ratio of vitamin D to carboxy-terminal telopeptide of type I collagen (β-CTX) on progression-free survival (PFS) and overall free survival (OS) in patients with NDMM. Methods The data of 431 consecutive patients with NDMM at Beijing Jishuitan Hospital from September 2013 to December 2022 were collected and retrospectively reviewed through our electronic medical record system. The measurement of 25-hydroxyvitamin D in the blood is an indicator of an individual’s overall vitamin D status. Results The serum levels of vitamin D were negatively correlated with β-CTX in NDMM patients. Of note, positive correlation between vitamin D and cholesterol levels in the serum was found in this study. The cohort (n = 431) was divided into two groups based on the serum ratio of vitamin D to β-CTX. Compared to the group with a higher vitamin D to β-CTX ratio, the group with a lower vitamin D to β-CTX ratio (n = 257, 60%) exhibited hypocholesterolemia, inferior PFS and OS, along with increased cases of ISS stage-III and R-ISS stage-III, a higher number of plasma cells in the bone marrow, and elevated serum calcium levels. Consistent with this, multivariate analysis confirmed that the vitamin D to β-CTX ratio was an independent unfavorable indicator for survival in NDMM patients. Conclusion Our data demonstrated the ratio of vitamin D to β-CTX in the serum is a unique biomarker for NDMM patients to identify the high-risk cases with poor prognosis, which is superior to vitamin D itself for predicting PFS and OS in NDMM. Also, it is worth mentioning that our data on the connection between vitamin D deficiency and hypocholesterolemia might help clarify novel mechanistic aspects of myeloma development.

[1]  E. V. van Roon,et al.  Effectiveness of a vitamin D regimen in deficient multiple myeloma patients and its effect on peripheral neuropathy , 2023, Supportive Care in Cancer.

[2]  Yue Yu,et al.  Potential role of 25(OH)D insufficiency in the dysfunction of glycolipid metabolism and cognitive impairment in patients with T2DM , 2022, Frontiers in Endocrinology.

[3]  C. Lu,et al.  Vitamin D inhibits bone loss in mice with thyrotoxicosis by activating the OPG/RANKL and Wnt/β-catenin signaling pathways , 2022, Frontiers in Endocrinology.

[4]  M. Rotondi,et al.  Vitamin D Reduces Thyroid Cancer Cells Migration Independently From the Modulation of CCL2 and CXCL8 Chemokines Secretion , 2022, Frontiers in Endocrinology.

[5]  W. Chng,et al.  Metabolic Vulnerabilities in Multiple Myeloma , 2022, Cancers.

[6]  N. Raje,et al.  Multiple myeloma cells induce lipolysis in adipocytes and uptake fatty acids through fatty acid transporter proteins. , 2021, Blood.

[7]  A. Farcaș,et al.  Modern markers for evaluating bone disease in multiple myeloma (Review). , 2021, Experimental and therapeutic medicine.

[8]  M. Kurokawa,et al.  Impact of vitamin D level at diagnosis and transplantation on the prognosis of hematological malignancy: a meta-analysis , 2021, Blood advances.

[9]  Li Su,et al.  Targeting lipid metabolism in multiple myeloma cells: Rational development of a synergistic strategy with proteasome inhibitors , 2021, British journal of pharmacology.

[10]  J. Zhuang,et al.  Major advances in the treatment of multiple myeloma in American Society of Hematology annual meeting 2020 , 2021, Chronic diseases and translational medicine.

[11]  A. Symeonidis,et al.  The Lipoprotein Transport System in the Pathogenesis of Multiple Myeloma: Advances and Challenges , 2021, Frontiers in Oncology.

[12]  U. Mellqvist,et al.  Serum Metabolomic Profiling Correlated with ISS and Clinical Outcome for Multiple Myeloma Patients Treated with High-dose Melphalan and Autologous Stem Cell Transplantation. , 2021, Experimental hematology.

[13]  S. Rhee,et al.  Lipid Level, Lipid Variability, and Risk of Multiple Myeloma: A Nationwide Population-Based Study of 3,527,776 Subjects , 2021, Cancers.

[14]  Z. Cai,et al.  Emerging agents and regimens for multiple myeloma , 2020, Journal of Hematology & Oncology.

[15]  J. Manson,et al.  Effect of Vitamin D3 Supplements on Development of Advanced Cancer , 2020, JAMA network open.

[16]  M. Crook,et al.  The Association between Metabolic Syndrome and Multiple Myeloma , 2020, Acta Haematologica.

[17]  N. Munshi,et al.  Vitamin D deficiency predicts for poor overall survival in white but not African American patients with multiple myeloma. , 2020, Blood advances.

[18]  T. Pabst,et al.  Reduced survival after autologous stem cell transplantation in myeloma and lymphoma patients with low vitamin D serum levels , 2020, Hematological oncology.

[19]  K. Watt,et al.  A retrospective analysis of the prevalence and clinical outcomes of vitamin D deficiency in myeloma patients in tropical Australia , 2020, Supportive Care in Cancer.

[20]  D. English,et al.  Vitamin D Status and Mortality: A Systematic Review of Observational Studies , 2019, International journal of environmental research and public health.

[21]  A. Mackensen,et al.  Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway , 2018, Leukemia.

[22]  K. Cashman,et al.  25-Hydroxyvitamin D as a Biomarker of Vitamin D Status and Its Modeling to Inform Strategies for Prevention of Vitamin D Deficiency within the Population. , 2017, Advances in nutrition.

[23]  B. de Courten,et al.  Plasma 25-Hydroxyvitamin D Is Related to Protein Signaling Involved in Glucose Homeostasis in a Tissue-Specific Manner , 2016, Nutrients.

[24]  F. Lammert.  Faculty Opinions recommendation of Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies. , 2016 .

[25]  Norma E. Conner,et al.  Advances and Challenges , 2016, The American journal of hospice & palliative care.

[26]  M. Rehli,et al.  Lenalidomide Enhances MOR202 Dependent Macrophage-Mediated Effector Functions Via the Vitamin D Pathway , 2015 .

[27]  C. Hofmeister,et al.  The Majority of Myeloma Patients Are Vitamin D Deficient, Unrelated to Survival or Cytogenetics , 2015 .

[28]  M. Duvic,et al.  Vitamin D deficiency in mycosis fungoides and Sézary syndrome patients is similar to other cancer patients. , 2014, Clinical lymphoma, myeloma & leukemia.

[29]  W. Grant,et al.  Vitamin D has a greater impact on cancer mortality rates than on cancer incidence rates , 2014, BMJ : British Medical Journal.

[30]  J. van de Peppel,et al.  Vitamin D and gene networks in human osteoblasts , 2014, Frontiers in physiology.

[31]  O. Franco,et al.  Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies , 2014, BMJ : British Medical Journal.

[32]  C. Gordon,et al.  Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. , 2011, The Journal of clinical endocrinology and metabolism.

[33]  C. Mathieu,et al.  Vitamin D: modulator of the immune system. , 2010, Current opinion in pharmacology.

[34]  A. Thrift,et al.  Systematic Review of Observational Studies , 2010, Neuroepidemiology.

[35]  S. Sereika,et al.  Lactation and bone turnover: a conundrum of marked bone loss in the setting of coupled bone turnover. , 2010, The Journal of clinical endocrinology and metabolism.

[36]  F. Greenway,et al.  An Endocrine Society Clinical Practice Guideline Endocrine and Nutritional Management of the Post-Bariatric Surgery Patient: , 2010 .

[37]  Shaji K. Kumar,et al.  Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma , 2009, American journal of hematology.

[38]  E. Terpos,et al.  Prevalence and significance of vitamin D deficiency in multiple myeloma patients , 2008, British journal of haematology.

[39]  F. Schmidt.  Meta-Analysis , 2008 .

[40]  M. Dimopoulos,et al.  The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma , 2007, Leukemia.

[41]  M. Holick,et al.  High prevalence of vitamin D deficiency, secondary hyperparathyroidism and generalized bone pain in Turkish immigrants in Germany: identification of risk factors , 2006, Osteoporosis International.

[42]  E. Terpos.  Biochemical markers of bone metabolism in multiple myeloma. , 2006, Cancer treatment reviews.